利拉鲁肽联合二甲双胍在2型糖尿病周围血管病变中的应用分析

Application of Lilalutide and Metformin in Peripheral Vascular Lesions of Type 2 Diabetes

目的探讨利拉鲁肽联合二甲双胍在2型糖尿病周围血管病变中的临床应用价值。方法选取2021年4月—2022年9月绵阳市中心医院收治的100例2型糖尿病周围血管病变患者为研究对象,按照随机数表法分为两组,各50例。对照组采用二甲双胍片治疗,观察组在对照组基础上使用利拉鲁肽治疗,两组均连续治疗3个月,即1个疗程。比较两组治疗过程中经皮氧分压变化情况,比较治疗前后两组体脂率及糖化血红蛋白变化情况,统计两组不良反应及临床效果。结果治疗1周后和治疗1个疗程后,观察组经皮氧分压分别为(80.5±6.5)mmHg和(86.9±7.6)mmHg,均高于对照组的(76.5±3.6)mmHg和(78.8±4.9)mmHg,差异有统计学意义(P<0.05)。治疗后,观察组体脂率为(24.3±2.1)%,显著低于治疗前的(30.3±2.9)%,且低于治疗后对照组的(27.8±2.5)%;观察组糖化血红蛋白水平为(6.1±0.5)%,显著低于治疗前的(8.2±1.1)%,且低于治疗后对照组的(7.2±0.9)%,差异有统计学意义(P<0.05)。观察组不良反应总发生率显著低于对照组,差异有统计学意义(P<0.05)。观察组有效率高于对照组,差异有统计学意义(P<0.05)。结论利拉鲁肽治疗2型糖尿病合并周围血管病变,可显著改善足背经皮氧分压,减低体脂率,调节糖化血红蛋白水平,且治疗安全性与有效性均较高。

Objective To explore the clinical application value of liraglutide combined with metformin in type 2 diabetes peripheral vascular disease.Methods 100 patients with type 2 diabetes peripheral vascular disease who were admitted to Mianyang Central Hospital from April 2021 to September 2022 were selected as the research objects,and were divided into two groups according to the random number table,50 patients in each group.The control group was treated with metformin tablets,while the observation group was treated with liraglutide on the basis of the control group.Both groups were treated continuously for 3 months,that is,one course of treatment.Compare the changes of transcutaneous partial pressure of oxygen during treatment between the two groups,compare the changes of body fat rate and glycosylated hemoglobin before and after treatment,and count the adverse reactions and clinical effects of the two groups.Results After one week of treatment and one course of treatment,the transcutaneous partial pressure of oxygen in the observation group was(80.5±6.5)mmHg and(86.9±7.6)mmHg,respectively,which were higher than those in the control group(76.5±3.6)mmHg and(78.8±4.9)mmHg,the difference was statistically significant(P<0.05).After treatment,the body fat rate in the observation group was(24.3±2.1)%,significantly lower than(30.3±2.9)%before treatment,and lower than(27.8±2.5)%in the control group after treatment;the level of glycosylated he moglobin in the observation group was(6.1±0.5)%,significantly lower than(8.2±1.1)%before treatment,and lower than(7.2±0.9)%in the control group after treatment,the difference was statistically significant(P<0.05).The total in cidence of adverse reactions in the observation group was significantly lower than that in the control group,the differ ence was statistically significant(P<0.05).The effective rate of the observation group was higher than that of the con trol group,the difference was statistically significant(P<0.05).Conclusion Liraglutide in the treatment of type 2 diabe tes mellitus complicated with peripheral vascular disease can significantly improve the percutaneous oxygen partial pressure,reduce the percentage of body fat,adjust the level of glycosylated hemoglobin,and has high safety and effi cacy.